News and Trends 22 Dec 2022 Spanish foodtech grows in 2022 Eatable Adventures, an agrifood accelerator, has presented the data from its annual study “The State of Foodtech in Spain 2022.” The report gathers information on the characterization and investment evolution of the Spanish foodtech entrepreneurial ecosystem. The report says 2022 has been a positive year for the sector in the country. Despite the macroeconomic context, […] December 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Watch: Biocant Park – a biotech hub in the heart of Portugal Biocant Park is a science and technology park specializing in biotechnology, with a unique innovation environment among the sector in Portugal. Located in Cantanhede, between Porto and Lisbon, the park aims to promote, develop and apply advanced knowledge in life sciences. Currently, the park has four buildings with laboratories and offices for companies, and a […] December 21, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 21 Dec 2022 Watch: Aphaia Pharma interview Aphaia Pharma is a Zug, Switzerland, headquartered clinical-stage biopharmaceutical company. It harnesses proprietary precision-targeted drug delivery technology to restore endogenous hormone release in the gastrointestinal tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia Pharma’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release […] December 21, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Watch: Araris Biotech at Bio-Europe Araris Biotech AG is a Swiss-headquartered company pioneering the development of its novel antibody-drug-conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown very high activity at […] December 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Watch: Mauritius – clinical trials and emerging biotech hub The Economic Development Board (EDB) in Mauritius commenced its operations as a statutory body in 2018 following the merger between the Board of Investment, Enterprise Mauritius and the Financial Services Promotion Agency. The overarching objective of the EDB is to ensure greater coherence and effectiveness in implementing policies and draw the vision for the economic […] December 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Biomica raises $20M to advance microbiome-based therapeutics pipeline Biomica Ltd., a subsidiary of Evogene Ltd., has signed a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities. The financing round will enable Biomica to develop its pipeline of microbiome-based therapeutics. The company […] December 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Poolbeg identifies new potential drug candidates for RSV infections Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked with OneThree to build a tailored AI approach that leverages Poolbeg’s RSV human challenge trial data to identify […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Ethris and DIOSynVax to develop mRNA betacoronavirus vaccine Ethris GmbH is to collaborate with U.K.-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of betacoronaviruses. The efforts will utilize Ethris’ mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilization platforms. The collaboration is founded on a $42 million award to DIOSynVax by the […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Anocca secures €25M to develop next-generation T-cell therapies for cancer Anocca, a fully integrated cell therapy biotechnology company, has secured €25 million ($26.5 million) venture debt financing from the European Investment Bank (EIB). Anocca’s CEO and co-founder Reagan Jarvis said: “We’re delighted that the EIB has chosen to support us as we build a critical piece of advanced biotechnology capability and infrastructure in Sweden. Anocca’s […] December 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Stem cell plasters could revolutionize heart surgeries Researchers at the University of Bristol in the U.K. funded by the British Heart Foundation (BHF) have developed ‘stem cell plasters’ to revolutionize the way surgeons treat children living with congenital heart disease, so they don’t need as many open-heart operations. Heart defects are the most common type of anomaly that develop before a baby […] December 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Pfizer diabetes and obesity study triggers Sosei Heptares windfall Sosei Group Corporation has been notified by Pfizer that the first subject in a phase 2 clinical trial has been dosed with Pfizer’s candidate PF-07081532. This triggers a $10 million payment to Sosei Heptares. PF-07081532 is a once-daily, next-generation oral small molecule GLP-1 receptor agonist in development for the treatment of type 2 diabetes and obesity. […] December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Artificial DNA can kill cancer Researchers at the University of Tokyo in Japan have used artificial DNA to target and kill cancer cells in a new way. The method was effective in lab tests against human cervical cancer- and breast cancer-derived cells, and against malignant melanoma cells from mice. The team created a pair of chemically synthesized, hairpin-shaped, cancer-killing DNA. […] December 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email